Inventiva (NASDAQ:IVA – Get Free Report) and Peak Pharmaceuticals (OTCMKTS:PKPH – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.
Insider & Institutional Ownership
19.1% of Inventiva shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 18.4% of Peak Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Inventiva and Peak Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Inventiva | N/A | N/A | N/A |
Peak Pharmaceuticals | N/A | N/A | -159.55% |
Volatility & Risk
Analyst Recommendations
This is a breakdown of recent ratings for Inventiva and Peak Pharmaceuticals, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Inventiva | 0 | 0 | 7 | 0 | 3.00 |
Peak Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Inventiva presently has a consensus target price of $17.00, indicating a potential upside of 655.56%. Given Inventiva’s higher possible upside, research analysts plainly believe Inventiva is more favorable than Peak Pharmaceuticals.
Earnings & Valuation
This table compares Inventiva and Peak Pharmaceuticals’ top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Inventiva | $17.48 million | 6.76 | -$119.51 million | N/A | N/A |
Peak Pharmaceuticals | N/A | N/A | -$160,000.00 | N/A | N/A |
Peak Pharmaceuticals has lower revenue, but higher earnings than Inventiva.
Summary
Inventiva beats Peak Pharmaceuticals on 7 of the 8 factors compared between the two stocks.
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
About Peak Pharmaceuticals
Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.